ArticleAnnals of hematology2026
Prediction of early death in peripheral T-cell lymphoma-NOS patients based on machine learning.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) is a highly aggressive and heterogeneous lymphoma subtype with a poor prognosis. This study aims to develop a machine learning-based model to predict early death (within 3 months of diagnosis) in PTCL-NOS patients using data from the SEER database (2016-2021). A total of 1,156 patients were included and randomly divided into training (n = 809) and validation (n = 347) sets. Key predictive factors were identified through Boruta and LASSO algorithms, including chemotherapy, radiotherapy, age, B symptoms, primary tumor site, Summary Stage, and Ann Arbor Stage. Seven machine learning models were constructed and evaluated using AUROC, AUPRC, calibration curves, Brier scores, and decision curve analysis. XGBoost demonstrated the best predictive performance (AUROC = 0.842 in training and 0.774 in validation). This study provides a novel and interpretable predictive tool that can aid in early risk stratification and personalized treatment planning for PTCL-NOS patients, ultimately improving clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.